February 6, 2024 Clinical Research/Diagn. Lab Top-10 Microscopy

Bruker Acquires Spectral Instruments Imaging, the Performance Leader in Preclinical In-Vivo Optical Imaging Systems

Bruker Acquires Spectral Instruments Imaging, the Performance Leader in Preclinical In-Vivo Optical Imaging Systems Acquisition Complements Bruker’s Preclinical Imaging Portfolio with In-Vivo Optical Imaging TUCSON, Ariz.–(BUSINESS WIRE)– Bruker Corporation (Nasdaq: BRKR) today announced that it has acquired Spectral Instruments Imaging LLC, a leader in preclinical in-vivo optical imaging systems. This acquisition fills a gap in... Read more

February 6, 2024 Uncategorized

MKS Instruments Declares Quarterly Cash Dividend

ANDOVER, Mass., Feb. 06, 2024 (GLOBE NEWSWIRE) — MKS Instruments, Inc. (NASDAQ: MKSI), a global provider of enabling technologies that transform our world, today announced that its Board of Directors has authorized a quarterly cash dividend of $0.22 per share, payable on March 8, 2024, to Read more

February 6, 2024 Lab Top-10 Life Science Tools PR/Corporate

Bruker Announces Date and Time of Fourth Quarter 2023 Earnings Release and Webcast

Bruker Announces Date and Time of Fourth Quarter 2023 Earnings Release and Webcast BILLERICA, Mass.–(BUSINESS WIRE)– Bruker Corporation (Nasdaq: BRKR) today announced it will report fourth quarter and fiscal year 2023 financial results before market opening on Tuesday, February 13, 2024. The Company will host a conference call and webcast at 8:30 a.m. Eastern Standard... Read more

February 6, 2024 Uncategorized

Xylem Reports Fourth-Quarter and Full-Year 2023 Results

Fourth-Quarter Highlights Orders of $2.0 billion , up 42% on a reported basis and 10% organically Revenue of $2.1 billion , up 41% on a reported basis and 9% organically Earnings per share of $1.10 , up 34%; $0.99 on an adjusted basis, down 1% Full-Year Highlights Revenue of $7.4 billion , up 33% Read more

February 5, 2024 Bio/Pharma/CRO Clinical Research/Diagn. Environ, Ag./Food & Bev Lab Top-10 M&A, Partnerships PAI Top-10 Product Launch

Danaher Launches Collaboration with Cincinnati Children's Hospital Medical Center Aiming to Improve Patient Safety in Early Drug Development

Danaher Launches Collaboration with Cincinnati Children’s Hospital Medical Center Aiming to Improve Patient Safety in Early Drug Development Danaher Beacon for Preclinical Drug Safety seeks to address major cause of failure in clinical trials Program will leverage automated liver organoid technology for drug toxicity screening Aims to expand genetic diversity of screening, accelerate therapy development,... Read more

February 5, 2024 Bio/Pharma/CRO Lab Top-10 Liq. Handling & Robotics Microscopy

Bruker Introduces the Ingenious Novel ‘Triceratops’ SPR #64 Surface Plasmon Resonance System for Drug Discovery at SLAS2024

Bruker Introduces the Ingenious Novel ‘Triceratops’ SPR #64 Surface Plasmon Resonance System for Drug Discovery at SLAS2024 Enables the Simultaneous Measurement of 64 Molecular Interactions BOSTON–(BUSINESS WIRE)– At the SLAS2024 International Conference and Exhibition, Bruker Corporation (Nasdaq: BRKR) today introduced the ground-breaking, new ‘Triceratops’ SPR #64 Surface Plasmon Resonance (SPR) instrument. The SPR #64 system... Read more

January 31, 2024 Environ, Ag./Food & Bev Lab Top-10 PAI Top-10 PR/Corporate

Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2023 Results

WALTHAM, Mass.–(BUSINESS WIRE)– Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter and Full Year 2023 Highlights Fourth quarter revenue was $10.89 billion, 5% lower versus the same quarter last year. Core organic revenue... Read more

January 30, 2024 Environ, Ag./Food & Bev Lab Top-10 PAI Top-10 PR/Corporate

Danaher Reports Fourth Quarter and Full Year 2023 Results

WASHINGTON, Jan. 30, 2024 /PRNewswire/ — Danaher Corporation (NYSE: DHR) (the “Company”) today announced results for the fourth quarter and full year 2023.  All results in this release reflect only continuing operations unless otherwise noted. Key Fourth Quarter 2023 Results Net earnings were $1.1 billion, or $1.50 per diluted common share and non-GAAP adjusted diluted... Read more